Cadrenal therapeutics, inc. common stockCVKD.US Overview

US StockHealthcare

(No presentation for CVKD)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

CVKD Overall Performance

CVKD AI Analysis & Strategy

CVKD Recent Performance

0.31%

Cadrenal therapeutics, inc. common stock

0.81%

Avg of Sector

-1.14%

S&P500

CVKD PowerScanner

CVKD Key Information

CVKD Valuation Metrics

CVKD Earnings Table

CVKD Profile

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.